Business Development

Strategic partnerships are an integral part of our corporate strategy. XORTX Pharma Corp. is seeking development and commercialization partners with proven competence in garnering new approvals, successfully launching products and are committed to developing novel products that meet the needs of both patients and physicians.

XORTX Pharma Corp. is developing a highly de-risked proprietary, reformulated xanthine oxidase inhibitor (XOI) for the treatment of orphan diseases as well as new XOI’s for more common diseases. XOI’s are a FDA approved class of drugs with a well known clinical safety profile, although are currently on approved for use in the treatment of gout, evidence suggests a much broader role should be pioneered.
Rigorous clinical studies suggest that uric acid may be causative in hypertension, inflammation, metabolic syndrome, diabetes and diabetic nephropathy/kidney injury.

Recent evidence from a many clinical studies reveals that decreasing serum uric acid (SUA) with xanthine oxidase inhibitors treatment can reduce markers of inflammation, progression of kidney injury including protienuria, glomerular filtration rate, hypertension, insulin resistance, and chronic kidney disease, and provides strong validating evidence that lowering uric acid should be part of a physician’s treatment options.

Autosomal Dominant Polycystic Kidney Disease (ADPKD)
ADPKD is an orphan indication disease representing perhaps 1:500-1:2000 individuals and a leading cause of end stage kidney renal disease. It is a disease representing up to 5% of all patients who have kidney failure before the age of 60 yrs.

Evidence from a variety of recent studies has accumulated supporting the concept that serum uric acid (SUA), when increased above the upper limit of normal is a “causative” mediator of hypertension, with strong secondary basic evidence suggesting a role of hyperuricemia (elevated serum uric acid) in the development of insulin resistance, diabetes and diabetic nephropathy.





Currently agents that specifically lower serum uric acid are only approved for the treatment of gout. These highly effective agents work well for the treatment of gout and have a long history of safe clinical use.

XORTX Pharma Corp.’s business model is built upon strong basic and recent clinical science successes, including:

Given the wealth of data on currently approved XOIs and novel mechanism of action, the introduction of these agents for the treatment and prevention of hypertension, diabetes and diabetic nephropathy represents a highly de-risked opportunity for developing new medical therapies in areas of large unmet medical need.

For more information please contact XORTX Pharma Corp.